Skip to content

NeuroSense Therapeutics Ltd.

NRSN NRSNW

CIK 0001875091

← back to feed
Revenue (TTM)
—
FY Dec 2025
Net Income (TTM)
−$11.13M
−9.0% YoY FY Dec 2025
EPS Diluted (TTM)
−$0.44
+18.5% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
—
FY Dec 2025
Net Margin
—
FY Dec 2025
Free Cash Flow (TTM)
−$7.68M
FY Dec 2025
Cash
$166K
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
32.56M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings